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Abstract
Background: Depending on the treatment to be investigated, a clinical trial could be designed to assess objectives
of superiority, equivalence or non-inferiority. The design of the study is affected by many different elements
including the control treatment, the primary outcome and associated relationships.
In some studies, there could be more than one outcome of interest. In these situations, benefit-risk methodologies
could be used to assess the outcomes simultaneously and consider the trade-off between the benefits against the
risks of a treatment.
Benefit-risk is used within the regulatory industry but seldom included within publicly funded clinical trials within
the UK. This project aims to gain an expert consensus on how to select the appropriate trial design (e.g. superiority)
and when to consider including benefit-risk methods.
Methods: The project will consist of four work packages:
1. A web-based survey to elicit current experiences and opinions,
2. A rapid literature review to assess any current recommendations,
3. A two-day consensus workshop to gain agreement on the recommendations, and
4. Production of a guidance document.
Discussion: The aim of the project is to provide a guideline for clinical researchers, grant funding bodies and
reviewers for grant bodies for how to select the most appropriate trial design and when it is appropriate to
consider using benefit-risk methods. The focus of the guideline will be on publicly funded trials however, the vision
is that the work will be applicable across research settings and we will connect with other organisations and
committees as appropriate.
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Background
Randomised controlled trials (RCTs) are a rigorous
methodology used to compare health technologies on a
multitude of outcomes in a real-world setting. Often, the
aim of an RCT is to provide evidence that a new health
technology (HT) is superior to current practice (super-
iority trial design). As more HTs come into practice, it is
common for current practice to be an existing HT. In
these circumstances, it is important that the RCTs show
the new HT is equivalent, or at least not inferior, to the
existing one on the primary health outcome and this re-
mains the primary outcome of the study (equivalence or
non-inferiority trial design). Equivalence suggests the
two HTs are “not too different” [1] to each other whilst
non-inferiority implies that the “new intervention is ‘not
unacceptably worse’ than the intervention used as the
control” [2].
Key elements of the study, such as the sample size, are
dependent on the selected primary outcome and related
trial design. However, particularly with equivalence and
non-inferiority designs, there are other important out-
comes within the study to consider. Considering mul-
tiple outcomes reflects the complexity of policy
decisions, where information on clinical effectiveness,
safety, cost, convenience and/or time could be consid-
ered when choosing whether to implement across the
National Health Service (NHS).
Benefit-risk (B-R) methodologies can be used in these
situations to consider the trade-off between outcomes
and evaluate “whether its benefits outweigh its risks” [3].
This is therefore providing a comparison of competing
treatments over multiple outcomes. B-R methodology is
already commonly used within the regulatory setting
where it is important for regulators to be able to evalu-
ate the benefits of a drug against its harms [4]. In 2007,
the European Medicine Agency (EMA) published a re-
port which showed the potential value of existing B-R
models and methods [5, 6] and further created decision-
making models for use in this area [7].
In the UK, the National Institute for Health Research
(NIHR) and the Medical Research Council (MRC) pub-
licly fund RCTs to provide the evidence to inform na-
tional policy decisions on HTs. Utilising the B-R
methods used in regulatory, drug trials in a publicly
funded setting requires additional considerations such as
economic outcomes and funder perspective.
There are signs that recent work in this area has begun
to influence practice [8]. However, these methods are
often considered during the analysis phase of the study
and not at the design stage which would help to ensure
all appropriate information is collected to complete this
work during analysis.
Further work is required to consider when different
trial designs are appropriate, evaluate the current
practice of using B-R in practice for these situations and
gain expert consensus on the appropriateness of B-R in
this setting to enable the production of more compre-
hensive guidance for this context.
Aims and objectives
The overall aim of this study is to provide consensus-
driven guidance for the inclusion of B-R approaches
within the design of NIHR/MRC funded RCTs.
This aim will be achieved by completing the following
specific objectives:
1. Review current practice of B-R methodology in re-
lation to different trial designs (superiority, equiva-
lence, non-inferiority),
2. Review recommended B-R methodologies and the
rationale for use within RCTs,
3. Achieve expert consensus on how to select an
appropriate trial design and when to consider
implementing the recommended B-R
methodologies,
4. Produce guidance to inform the inclusion of B-R
methodologies within RCTs for NIHR/MRC trials.
Methods
The project has been split into four work packages
(WPs) to represent the four objectives.
 WP1. A survey of relevant researchers about their
experiences of using B-R methodologies within
RCTs,
 WP2. A rapid literature review to assess any current
recommendations for B-R methodologies,
 WP3. A two-day consensus workshop to gain agree-
ment on the recommended design and methods that
could be used in the NIHR/MRC setting,
 WP4. Create a guidance document to aid
researchers on designing studies and potentially
including B-R methodologies within NIHR/MRC
grant applications.
WP1—survey
A web-based survey of current practice will be con-
ducted using the Qualtrics [9] platform. The main ob-
jective of the survey is to elicit current use and initial
opinions on the use of B-R methodologies in RCTs (in-
dustry or publicly funded). In addition, it will be used to
identify any methodological updates currently in pro-
gress and understand the information required to be
within the final guidance document.
The survey will be sent via email to a range of key
stakeholders within clinical trials including representa-
tives of trial funding bodies, experts and researchers
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known to be working in the field to get a range of
experiences.
Summary statistics will be completed on the results from
the survey and presented as means and standard deviations
or medians and inter-quartile ranges for continuous data
and counts and percentages for categorical data. No formal
statistical testing will take place on the survey data.
WP2—literature search
A rapid methodological [10] review will be conducted of
the published and unpublished guidance on B-R meth-
odology using a pearl growing technique. Pearl growing
is a method of iteratively developing search strategies
based on the thesaurus and free-text terms associated
with articles of known relevance [11]. This will comple-
ment the review completed by the PROTECT group
which focussed on B-R in drug development [12] by
concentrating on B-R methodologies recommended for
use in RCTs.
Eligible material will be published and unpublished
guidance and methodological articles in English propos-
ing B-R methodology between 1999 and 2019. This
chosen time period was to ensure sufficient article iden-
tification without repetition and was supported by the
timelines presented by Garrison [13]. Formal search
strategies will search MEDLINE and Web of Science
starting with key terms and papers known to the re-
search team to identify MeSH headings for the formal
search strategy. Informal search strategies will focus on
Google Scholar, grey literature, reference and citation
tracking [14]. The review will be registered on
PROSPERO.
The review will link sources to broad methodological
categories with other variables including context, ration-
ale, procedures and author-identified methodological
strengths and limitations. No formal, pre-specified as-
sessment of methodological quality will take place with
deductive reasoning - that bias could be a formal logical
consequence of the proposed method—explicated in the
narrative synthesis. We will apply the constant compari-
son method to extracted data [10]. Narrative synthesis
will involve one or more tables of B-R rationale and
practices.
The results from the literature search will be coupled
with the survey responses (WP1) to produce an overview
of current possible methods of B-R, their potential uses
in RCTs and any strengths and weaknesses found within
the literature related to each one. These findings will
then feed into the workshop to facilitate discussion
about appropriate B-R methodologies.
WP3—workshop
To reach consensus on how to select a trial design and
when to use B-R methodologies, a 2-day expert
consensus workshop will be completed which will in-
clude presentations, discussions and use the Nominal
Group Technique (NGT) to reach consensus as appro-
priate [15]. NGT is an interactive multi-stage approach
which is designed to combine opinion into group con-
sensus during a structured face-to-face meeting. This fa-
cilitates the generation of a wide range of ideas,
encourages equal participation, helps to avoid conflict
and the possibility of some viewpoints dominating and
crucially enables the achievement of a credible solution
within a short timeframe.
Elements of the workshop will be:
1. A briefing document which summarised the
findings of the survey and literature review
(containing all B-R approaches identified) will be
sent to workshop participants in advance;
2. Presentations will be used to set the scene of the
workshop and give all the necessary background
information to the topic. This will from different
perspectives, e.g. methodology and application so
that all outlooks can be considered in the
discussions.
3. Brainstorming round/s—panel members will be
asked to record their individual thoughts on
elements of the guidance such as designing
superiority/non-inferiority studies and using B-R
methodologies. A “round robin” sharing of ideas will
then be completed to allow identification of all po-
tential approaches, followed by a structured whole
group discussion;
4. A preliminary rating round will be completed to
gain preferences on design and use of B-R method-
ologies, the results of which will be considered
within a second structured group discussion; and
5. A second, final round of rating will be completed to
elicit the final preferences of approaches.
Participants of the workshop will be co-applicants of
the project along with additional members identified
from the responses to the survey. Participants will be in-
vited to aim for input across the industry, academia, fun-
ders and policy makers from within the UK and
internationally if felt appropriate.
Key discussions from the workshop will be recorded,
transcribed and analysed using thematic analysis [16]
supported by the NVivo software. These results will be
used to provide further detail to the preferences stated
within the NGT.
WP4—guidance document
Using the information gained in WP1–3 with a focus on
results from the workshop, a guidance document will be
written to incorporate the opinions and preferences of
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the expert group. The guidance will describe the
methods for selecting a trial design, when it is appropri-
ate to use B-R methods and how this relates to the dif-
ferent trial designs. Any key recommendations about
particular methods will also be made as appropriate.
Recommendations will be illustrated using RCT case
studies.
Sample size
There will be no limit to the number of participants
approached for inclusion in the survey and it is antici-
pated there will be between 25 and 30 participants at the
workshop. Guidance on consensus methodology is not
overly prescriptive on sample size. Whilst Murphy et al.
(1998) [17] recommend between 6 and 12 participants,
it was hoped to accommodate a larger number for this
project, in-keeping with previous similar work [18], to
ensure that all stakeholder groups are represented.
Dissemination
The guidance document produced from this project will
be reported to the MRC and NIHR as well as other
funding bodies and stakeholders. The guidance will be
published in an appropriate peer-reviewed journal and
presented at relevant conferences.
Project management
The co-applicants of the study will make up an oversight
committee which will provide strategic input to the
focus, methodology and outputs of the project. These
members have a wide range of experience of clinical tri-
als within academia and the pharmaceutical industry to
give a range of perspectives to direct the project. There
will be two scheduled meetings with this group before
the workshop to provide an update to applicants and get
feedback as required.
A working group, consisting of SJ, JC, DH and NT,
will manage the day-to-day running of the project with
monthly meetings scheduled throughout the duration of
the project to keep up to date with progress.
Discussion
A guideline on selecting trial designs and using B-R
methodologies within NIHR/MRC funded clinical trials
could help facilitate their application in NHS policy deci-
sions. Our aim is to provide a guideline for clinical re-
searchers, grant funding bodies and reviewers for grant
bodies. The focus of the guideline will be on publicly
funded trials; however, the vision is the work will be ap-
plicable across research settings and we will connect
with other organisations and committees as appropriate.
Trial status
The WP1 survey was open between 21 May 2019 and 31
of July 2019. The WP2 full literature search was com-
pleted in July 2019 and extraction completed in August
2019. WP3, the workshop, ran in September 2019 and
the results from this and WP4, the guidance document
will be completed by April 2020. The current protocol is
Version 2 dated 10 May 2019. Recruitment within this
project was specific to each stage and the inclusions of
other experts’ input to the project have no limit. Al-
though the data from the workshop has been collected,
the information to include in the guidance document
(the key output from the study) will have input and add-
itional data included, as appropriate, from expert mem-
bers until saturated and the end date for inclusion
within the project will be once the guidance has been
submitted and the project closed down (April 2021).
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